Skip to Content

    This biotech manufacturer, a publicly listed joint venture of two companies affiliated with the Samsung conglomerate, brought in only $400 million in revenue in 2017. But through partnerships with Biogen and AstraZeneca, it holds a stake in the world’s largest pipeline for biosimilar generic drugs—a pipeline that analysts believe can generate annual revenue growth of 40% to 60% for years to come. In July, South Korean regulators ruled that the company violated accounting standards in structuring one of its partnerships and referred the case to prosecutors. In a statement, the company said its actions were legal.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Overall Score-
    Sector
    Health Care
    Industry
    Life Sciences Tools and Services
    CEO
    Tae-Han Kim
    Websitehttp://www.samsungbiologics.com
    Employees1,767
    HQ Location
    Incheon, South Korea
    Revenues ($M) (Past 12 Months)$501
    Profits ($M) (Past 12 Months)$-99
    Market Value as of Oct. 10, 2018 ($M)$28,326